Renal tubular disease in the era of combination antiretroviral therapy
- PMID: 26372389
- DOI: 10.1097/QAD.0000000000000736
Renal tubular disease in the era of combination antiretroviral therapy
Abstract
Objectives: To describe the spectrum of renal tubular disease (RTD) in HIV-positive patients and its association with exposure to antiretroviral therapy (ART).
Design: Review of 265 consecutive renal biopsies from HIV-positive patients attending eight clinics in the United Kingdom between 2000 and 2012.
Methods: We described the clinical characteristics of patients with RTD and compared current/recent exposure (at the time of, or up to 3 months prior to the date of biopsy) to potentially nephrotoxic ART [tenofovir (TDF), atazanavir (ATV), indinavir (IDV) and lopinavir/ritonavir (LPV/r)]. We also analysed the incidence of RTD in the UK CHIC cohort. Kruskall-Wallis, analysis of variance and Fisher's exact tests were used to evaluate between-group differences.
Results: Of the 60 RTD cases, 54 (90%) were included in the analyses. RTD comprised of three distinct patterns: acute tubular injury (ATI, n = 22), tubulo-interstitial nephritis (TIN, n = 20) and interstitial fibrosis and tubular atrophy (IFTA, n = 12). Compared with TIN and IFTA, ATI cases were less likely to be of black ethnicity (10 vs. 42-55%; P = 0.006), more likely to be on ART (100 vs. 55-68%; P = 0.001), with HIV-RNA below 200 copies/ml (100 vs. 54-58%; P < 0.001), and more likely to have current/recent exposure to TDF (P < 0.001). We did not find evidence for an association between exposure to TDF, ATV/r or LPV/r and either TIN or IFTA.
Conclusion: RTD was present in approximately 20% of renal biopsies and comprised three distinct injury patterns with considerable clinical overlap. ATI was associated with TDF exposure, although the overall incidence of biopsy-defined ATI was low.
Comment in
-
Frequency of atazanavir-associated leukocyturia development and renal function decline.AIDS. 2016 Jun 1;30(9):1488-9. doi: 10.1097/QAD.0000000000001061. AIDS. 2016. PMID: 27167012 No abstract available.
Similar articles
-
Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients.AIDS. 2015 Sep 10;29(14):1785-1792. doi: 10.1097/QAD.0000000000000760. AIDS. 2015. PMID: 26372384 Free PMC article.
-
Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.Curr HIV Res. 2019;17(5):324-334. doi: 10.2174/1570162X17666191025115508. Curr HIV Res. 2019. PMID: 31654514
-
Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study.AIDS Res Hum Retroviruses. 2013 Feb;29(2):256-65. doi: 10.1089/aid.2011.0275. Epub 2012 Aug 3. AIDS Res Hum Retroviruses. 2013. PMID: 22730929 Clinical Trial.
-
Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity.AIDS. 2014 Mar 13;28(5):621-32. doi: 10.1097/QAD.0000000000000103. AIDS. 2014. PMID: 24983540 Review.
-
Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.HIV Med. 2009 Oct;10(9):527-35. doi: 10.1111/j.1468-1293.2009.00724.x. HIV Med. 2009. PMID: 19785663 Review.
Cited by
-
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.AIDS. 2017 Feb 20;31(4):485-492. doi: 10.1097/QAD.0000000000001353. AIDS. 2017. PMID: 28121667 Free PMC article.
-
HIV and the kidney in the acute medical unit.Clin Med (Lond). 2015 Dec;15(6):571-6. doi: 10.7861/clinmedicine.15-6-571. Clin Med (Lond). 2015. PMID: 26621951 Free PMC article.
-
Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients.BMC Infect Dis. 2017 Jun 5;17(1):396. doi: 10.1186/s12879-017-2497-3. BMC Infect Dis. 2017. PMID: 28583112 Free PMC article.
-
Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.PLoS One. 2021 May 11;16(5):e0249760. doi: 10.1371/journal.pone.0249760. eCollection 2021. PLoS One. 2021. PMID: 33974624 Free PMC article.
-
Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney Int. 2018 Mar;93(3):545-559. doi: 10.1016/j.kint.2017.11.007. Epub 2018 Feb 3. Kidney Int. 2018. PMID: 29398134 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials